Twenty-two years in and Alnylam Pharmaceuticals is still not raking in any profit. But that’s a testament to the company’s R&D focus, because it takes more than one or two successful drugs to make a lasting mark on the biopharma industry.
That biotech pluck keeps Alnylam reliant on its RNAi acumen and a strong R&D engine, but also product launches that stick the landing.
“We’re still not profitable, so we have to be very thoughtful about how we optimize and how we justify costs,” said Tolga Tanguler, chief commercial officer and executive vice president at Alnylam.
The company’s latest win came in March with a U.S. approval for its drug Amvuttra to treat ATTR amyloidosis with cardiomyopathy. Leading the commercial launch, Tanguler is aiming for Amvuttra to become a first-line treatment due to the severity of the rare…